文献速递老年慢病共病管理衰弱、肌少症与跌倒

常规血液学指标作为衰弱可扩展生物标志物:系统综述与荟萃分析

Routine Hematologic Indices as Scalable Biomarkers for Frailty: A Comprehensive Systematic Review and Meta-Analysis.
PubMed 文献 · J Am Med Dir Assoc · 2026-09-09

结果显示这些指标与不良结局相关,尤其在急性冠脉综合征相关人群中,但需前瞻性研究验证其增量预后价值。

要点

  • CALLY升高与全因死亡降低相关(HR 0.46,95%CI 0.24-0.87)。
  • NPAR与死亡关联最一致(HR 1.88,95%CI 1.71-2.08;I²=4.8%)。
  • LAR对死亡的合并效应估计最大(HR 2.50,95%CI 1.78-3.51)。

核心结论

  • 白蛋白基生物标志物与冠心病患者不良结局相关,尤其在ACS相关人群中,不同标志物和临床终点呈现不同预后模式。
  • 这些常规可用指标可能为风险分层提供补充信息,但需前瞻性研究确定其超越现有风险评估的增量预后价值和临床效用。

主要发现

  • CALLY升高与全因死亡降低相关(HR 0.46,95%CI 0.24-0.87),与MACE呈方向性保护但无统计学意义(HR 0.44,95%CI 0.18-1.08)。
  • CAR/hsCAR升高在ACS相关队列中与死亡增加(OR 1.61,95%CI 1.09-2.38)和MACE增加(HR 1.37,95%CI 1.21-1.56)相关。
  • NPAR与死亡关联最一致(HR 1.88,95%CI 1.71-2.08;I²=4.8%),与MACE关联较不稳定(HR 1.86,95%CI 0.56-6.13)。
  • LAR对死亡的合并效应估计最大(HR 2.50,95%CI 1.78-3.51)。
  • 判别分析中,CAR对长期MACE判别最均衡,NPAR对长期MACE规则入组特征最强,CAR和CALLY对死亡判别最佳。

临床怎么用

  • 这些常规血液学指标可能辅助冠心病患者风险分层,但原文未报告具体临床决策阈值或干预方案。

局限性

  • 原文指出需前瞻性研究确定这些指标的增量预后价值和临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To systematically evaluate the associations of albumin-based biomarkers, including the C-reactive protein-to-albumin ratio (CAR/hsCAR), neutrophil percentage-to-albumin ratio (NPAR), lactate-to-albumin ratio (LAR), and C-reactive protein-albumin-lymphocyte (CALLY) index, with mortality and major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD), and to compare their prognostic and discriminative performance. DESIGN: Systematic review and meta-analysis. SETTING AND PARTICIPANTS: Thirty-four studies involving 47,763 patients with CAD were included, encompassing predominantly acute coronary syndrome (ACS)-related populations as well as broader coronary and cardiovascular cohorts. METHODS: We systematically evaluated albumin-based biomarkers, including CAR/hsCAR, NPAR, LAR, and CALLY. Pooled associations with mortality and MACE were estimated using effect measures reported by the original studies. Discriminative performance and potential clinical utility were also evaluated where data were available. RESULTS: Higher CALLY values were associated with lower all-cause mortality (HR 0.46, 95% CI 0.24-0.87) and showed a directionally protective but nonsignificant association with MACE (HR 0.44, 95% CI 0.18-1.08). Elevated CAR/hsCAR was associated with increased mortality (OR 1.61, 95% CI 1.09-2.38) and MACE (HR 1.37, 95% CI 1.21-1.56) in ACS-related cohorts. NPAR showed the most consistent association with mortality (HR 1.88, 95% CI 1.71-2.08; I² = 4.8%), whereas its association with MACE was less stable (HR 1.86, 95% CI 0.56-6.13). LAR showed the largest pooled effect estimate for mortality (HR 2.50, 95% CI 1.78-3.51). In discriminative analyses, CAR showed the most balanced performance for long-term MACE, NPAR showed the strongest rule-in profile for long-term MACE, and CAR and CALLY showed the best discrimination for mortality. CONCLUSIONS AND IMPLICATIONS: Albumin-based biomarkers are associated with adverse outcomes in CAD, particularly in ACS-related populations, with distinct prognostic patterns across biomarkers and clinical endpoints. These routinely available indices may provide complementary information for risk stratification; however, prospective studies are needed to determine their incremental prognostic value and clinical utility beyond established risk assessment approaches.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Yang YW, Gao L, Zhang Y, et al. Routine Hematologic Indices as Scalable Biomarkers for Frailty: A Comprehensive Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2026. PMID: 42715816. doi:10.1016/j.jamda.2026.106479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。